Skip to Content
Biotechnology and health

Up to 40 percent of DNA results from consumer genetic tests might be bogus

March 27, 2018

A new study has found that direct-to-consumer genetic tests, like those marketed by 23andMe, Ancestry.com, Family Tree DNA, and MyHeritage, can be used to obtain innacurate results.

Data dump: Most of these tests use a technique called genotyping to provide information about a person’s ancestry, risk of developing certain disorders, or status as a carrier of specific diseases. Some companies also make the raw genotyping data available to customers upon request. People can then take that data to third-party companies to interpret for a fee.

Lost in interpretation: Scientists at Ambry Genetics, a diagnostics company that also interprets data from consumer DNA tests, looked at this raw genotyping data from 49 people. They found that 40 percent of the variants noted in the raw data were false positives—that is, they indicated that a particular genetic variant was present when it wasn’t. Most of the false-positive calls were of cancer-linked genes. In eight instances, third-party interpretation services misunderstood the variants present. 

Buyer beware: Unlike clinical genetic tests that require a physician’s sign-off, direct-to-consumer tests are not meant to provide a diagnosis, and they offer risk information for only a limited number of conditions. If a consumer DNA kit uncovers a surprising or noteworthy genetic variant, the authors advise people to seek out doctor-ordered genetic tests to confirm the results.  

Deep Dive

Biotechnology and health

What to know about this autumn’s covid vaccines

New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.

A biotech company says it put dopamine-making cells into people’s brains

The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.

Tiny faux organs could crack the mystery of menstruation

Researchers are using organoids to unlock one of the human body’s most mysterious—and miraculous—processes.

After 25 years of hype, embryonic stem cells are still waiting for their moment

Research roadblocks and political debates have delayed progress—but scientists are inching closer to delivering a cure. 

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.